Searchable abstracts of presentations at key conferences in endocrinology

ea0063p1151 | Reproductive Endocrinology 2 | ECE2019

Psychological issues in turner syndrome

Calanchini Matilde , Fabbri Andrea , Turner Helen E

Introduction: Turner syndrome (TS) affects 1/1700 female, is due to total/partial lack of an X chromosome and besides short stature and gonadal dysgenesis, is associated with several comorbidities. No defined psychiatric condition has been related to TS. However, several case-reports have appeared in psychiatric literature, and TS is reported to be three times more prevalent in schizophrenia compared with the general female population.Aim: To evaluate th...

ea0049gp203 | Thyroid 1 | ECE2017

The oxford multidisciplinary thyroid eye disease (TED) clinic; can short waiting times and use of steroid sparing agents (SSA) reduce total steroid dose and requirement for surgery/radiotherapy?

Turner Helen , David Joel , Norris Jonathan

Introduction: The Oxford multidisciplinary thyroid eye disease (TED) clinic comprising an oculoplastic surgeon, rheumatologist and endocrinologist with access to orthoptics, neuroradiology and radiotherapy was established in 2013. The aim was to facilitate rapid referral and treatment in a specialist centre in keeping with Amsterdam Declaration. Early use of steroid sparing agents (SSA) and recently rituximab forms part of the treatment regimen.Methods: ...

ea0028p45 | Clinical practice/governance and case reports | SFEBES2012

A protocol for avoidance of post-thryoidectomy hypocalcaemia, results of first 12 months’ audit

Alexandre Leo , Pain Simon , Turner Jeremy

Background: Total and completion thyroidectomy are commonly performed operations for the treatment of thyroid disease. Post-operative hypocalcaemia is a frequent complication of this surgery, and is associated with morbidity and prolonged length of stay (LOS).Methods: In January 2010 we introduced a protocol for the avoidance and management of post-operative of hypocalcaemia based on risk-stratification by post-operative PTH levels in patients undergoing...

ea0024p52 | (1) | BSPED2010

UK trends in the treatment of young patients with thyrotoxicosis using radioiodine

Turner N , Driver I , Cheetham T

Background: Radioiodine (RI) treatment of benign thyroid disease in young people has received a lot of attention recently with authorities in the US highlighting an encouraging short and medium term safety record. In this audit we surveyed treatment centres in the UK to assess the trend in RI administration in patients aged 21 years and under.Methods: Over sixty Medical Physics Departments, dispersed to represent a suitable geographical coverage pattern ...

ea0016p671 | Steroid receptors | ECE2008

(Lack of) Epigenetic variability in the human glucocorticoid receptor promoter CpG island

Turner Jonathan , Pelascini Laetitia , Muller Claude

Tissue and cell type specific control of glucocorticoid receptor (GR) levels is thought to occur through the usage of alternate promoters, and associated non-coding alternate first exons. The vast majority of the known alternative first exons are located within a 3.2 kbp CpG island. Methylation of certain CpG dinucleotides within the rat Gr promoter has been implicated in changes in hippocampal GR expression levels and the resultant disturbances in the HPA axis.<...

ea0007p108 | Endocrine tumours and neoplasia | BES2004

Systemetic dose extension of octreotide LAR - the importance of individual tailoring of treatment

Thornton-Jones V , Wass J , Turner H

VA Thornton-Jones, JAH Wass and HE Turner, OBJECTIVE: Despite a recommended injection frequency of 4 weekly(4w), prolonged duration of GH suppression has been observed in some patients following treatment with long-acting somatostatin analogues. The aim of our study was to perform a prospective systematic study to determine whether extending the interval between doses of Octreotide LAR (LAR) allows maintenance of 'safe' GH in selected patients with acromegaly.<p class="abs...

ea0005p101 | Diabetes, Metabolism and Cardiovascular | BES2003

Octreotide LAR - a patient and nurse perspective

Thornton-Jones V , Turner H , Wass J

Background: Octreotide LAR is used in the treatment of Acromegaly and is effective in reducing growth hormone levels in the majority of patients. With the introduction of the Endocrine Specialist Nurse it has been possible to take their care into the community.Method: A questionnaire was administered for both patients and practice nurses, to enable us to highlight the benefits and identify any problems. It was sent to 27 patients who receive Octreotide LAR and 27 GP Surger...

ea0005p202 | Reproduction | BES2003

Complications of testosterone replacement in men with primary and secondary hypogonadism

Meston N , Turner H , Wass J

IntroductionTestosterone replacement for hypogonadism comes in a variety of galenical forms. Side effects include prostatic enlargement and polycythaemia. Furthermore careful scrutiny for prostatic carcinoma is essential. We audited 205 male patients from one clinical centre to assess dose, frequency and complications profile and the effectiveness of biochemical and haematological monitoring. Data of this type in a group of this size has not been previously published.M...

ea0003p31 | Clinical Case Reports | BES2002

What is the natural history of scalp hairloss in association with the use of somatostatin analogues in the treatment of acromegaly?

Bradley K , Turner H , Wass J , Colao A

Background & Methods: Occasional case reports of individual patients with scalp hairloss while receiving somatostatin analogues for acromegaly led us to audit similar patients in our departments.Results: Ten patients (four men, mean age at diagnosis 44.7years [range 26-65years]) who have received somatostatin analogues either initially as primary therapy (50%) or as post-surgical treatment (50%) for uncured acromegaly reported significant scalp hair...

ea0003p47 | Clinical Case Reports | BES2002

Thromboembolism in patients with Cushing's disease - a retrospective case review

Ahmad B , Turner H , Wass J

Patients with Cushing's disease are well known to develop easy bruising due to cortisol excess but are also predisposed to thrombembolism.We present four patients who developed thromboembolism during active Cushing's disease.Case 1- Four year history of hypertension, osteoporosis and central obesity. A DVT developed prior to referral. Initial urinary free cortisol(UFC)was 524nmol/24hrs. Inferior petrosal sinus sampling indicated ...